However, KRAS mutations were not strongly associated with improved PFS in the MDACC validation cohort (HR 0.84, 95% CI 0.45–1.6, P = 0.17), reflecting the heterogeneity of this NSCLC subgroup27–30. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.